(-0.04%) 5 476.50 points
(-0.07%) 38 791 points
(0.01%) 19 922 points
(0.34%) $80.60
(1.29%) $2.82
(0.22%) $2 334.20
(-0.21%) $29.33
(-0.18%) $969.20
(0.01%) $0.932
(-0.16%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19...
Stats | |
---|---|
Šios dienos apimtis | 62 614 |
Vidutinė apimtis | 475 709 |
Rinkos kapitalizacija | 4.52M |
EPS | $-0.460 ( Q1 | 2024-05-14 ) |
Kita pelno data | ( $-0.400 ) 2024-08-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.490 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0150 (1.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Springer Graig | Buy | 100 000 | Options |
2024-01-05 | Springer Graig | Buy | 25 000 | Options |
2024-01-05 | Sarnoff David | Buy | 25 000 | Options |
2024-01-05 | Pavell Jeff | Buy | 25 000 | Options |
2024-01-05 | Linsley Wayne | Buy | 25 000 | Options |
INSIDER POWER |
---|
100.00 |
Last 63 transactions |
Buy: 4 493 741 | Sell: 2 121 250 |
Tūris Koreliacija
Hoth Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Hoth Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Hoth Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-2.30 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-2.30 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-66 834.00 (0.00 %) |
EPS: | $-9.75 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-28.95 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.